WST West Pharmaceutical Services
FY2025 10-K
West Pharmaceutical Services (WST) filed its fiscal year 2025 10-K annual report with the SEC on Feb 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Manufacturer of integrated containment and delivery systems for injectable drugs, including proprietary packaging and contract manufacturing
- • Emphasis on patient-centric self-injection devices combined with connected health technologies for improved treatment adherence
Risk Factors
- • Regulatory risk: U.S. tariffs and retaliatory tariffs in operational jurisdictions; impact on supply chain currently not material but dynamic and monitored closely
- • Macroeconomic risk: $572.2 million cash held outside the U.S., exposing liquidity to foreign exchange volatility and global economic conditions
Financial SummaryXBRL
Revenue
$3.1B
Net Income
$494M
Gross Margin
35.9%
Operating Margin
19.0%
Net Margin
16.1%
ROE
15.5%
Total Assets
$4.3B
EPS (Diluted)
$6.79
Operating Cash Flow
$755M
Source: XBRL data from West Pharmaceutical Services FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on West Pharmaceutical Services
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.